Tetra Bio-Pharma Files Patent for the Treatment of Cancer and Ocular Disease
Tetra Bio-Pharma Files Patent for the Treatment of Cancer and Ocular Disease
Momentum Public Relations
Press Release: May 17, 2017
OTTAWA, ONTARIO–(Marketwired – May 17, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:GRPOF), today announced that Tetra has submitted a provisional patent application with the U.S. patent and trademark office for a pharmaceutical drug formulation to treat various forms of cancer and ocular disease.
The global market for cancer drugs has hit US$100 billion in annual sales, and could reach US$147 billion by 2018, according to a new report by the IMS Institute for Healthcare Informatics. According to Transparency Market Research, the global ophthalmic drug market is expected to reach US$21.6 billion by 2018 due to high incidence of eye-related disorders amongst geriatrics. The provisional patent aims to protect new pharmaceutical combinations of cannabinoids and terpenoids to inhibit a specific signaling pathway, known as Hedgehog (Hh), and their use to combat human diseases.
“Filing of this provisional patent marks the launch of an innovative and exciting project that could not only impact patients suffering from a variety of human diseases, but also further Tetra’s interests in developing and commercializing novel cannabinoid-based pharmaceutical drugs,” said Dr. Guy Chamberland, Chief Scientific Officer of Tetra. “The rationale forming the basis for this project is well founded and our research team has extensive scientific experience in the Hh field. We look forward to quickly advancing the project through key academic collaborations, with the ultimate goal of developing multiple pharmaceutical treatments.”
Background Information:
Hh signaling is a critical developmental molecular signaling pathway and inappropriate over activation of Hh is causal in several types of human tumors, including medulloblastoma, basal cell carcinoma, rhabdomyosarcoma, and multiple forms of leukemia, as well as liver, stomach, small cell lung, prostate, and breast cancers. Hh signaling also regulates the formation and remodeling of blood vessels, and aberrant blood vessel growth is implicated in several human diseases. The eye is particularly vulnerable to dysfunctional angiogenesis and neovascularization, such as in the case of diabetic retinopathy, age-related macular degeneration, neovascular glaucoma, retinal vein occlusion and retinopathy of prematurity, where inappropriate ocular blood vessel growth often leads to irreversible blindness if left untreated.
Currently, there are few clinically approved treatments for Hh-pathway-dependent cancers and drug resistance remains a major hurdle. As well, current treatment approaches to neovascular and angiogenic ocular disease are insufficiently effective and have significant adverse effects. Thus, there is a large need to develop novel therapies to treat human cancers and ocular disease related to blood vessel growth. Recently, cannabinoids have emerged as novel and potent inhibitors of the Hh signaling pathway and terpenoids have been shown to modulate the effects of cannabinoids through an undefined mechanism. Tetra looks to capitalize on these recent findings by filing a provisional patent for the use of cannabinoids in combination with terpenoids to treat Hh related cancer growth and aberrant blood vessel growth in the eye. Securing a provisional patent and achieving the freedom to operate is an important first step in the realization of this project.
About Tetra-Bio Pharma:
Tetra Bio-Pharma is a multi subsidiary publicly traded company (CSE:TBP)(OTCQB:GRPOF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.
Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.
The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
(514) 360-8040 Ext. 203
edward@tetrabiopharma.com
- Published in Medical Marijuana, News Home, Tetra Bio Pharma
Tetra Bio-Pharma: The Canadian Pioneer in Cannabis-Based Pharma for Pain Relief in Cancer Patients
Momentum PR ‘s client, Tetra Bio-Pharma is listed on the Canadian Securities Exchange under the symbol TBP as well as on the OTCQB in the US under the symbol GRPOF
Momentum PR is pleased to have produced an informative and comprehensive report on Tetra Bio-Pharma available on the Momentum PR LinkedIn page.
Tetra Bio-Pharma Highlights:
- – Canadian-based pioneer, innovator and first to market in cannabis-based pharmaceuticals- Global medical marijuana market is estimated to reach US$55.8 billion by 2025- Tetra Bio-Pharma is the first and only bio-pharma company in North-America focused on cannabinoid (CBD) clinical stage pain relief products- Tetra is the only bio-pharma company currently running a double-blind Phase 1 study with organically-grown cannabis
– Positive outcome from trials will result in for North-American Drug Identification Numbers (DIN), thus qualifying prescriptions for insurance coverage.
– Strategic partnership with Aphria Inc. announced in November 2016 and solidified in April 2017
Tetra Bio-Pharma is a Canadian-based pioneer, innovator and first market mover in developing cannabis-based pharmaceuticals. These are used for the treatment of cancer-related pain and the resultant nausea, as well as anorexia and Post Traumatic Stress Disorder (PTSD).
The global medical marijuana market is estimated to reach US$55.8 billion by 2025, according to Grand View Research. Health Canada has stated that they expected a mature medical marijuana market worth C$1.3 billion by 2024 in Canada alone.
Tetra Bio-Pharma is the first and only bio-pharmaceutical company in North-America that is focused on cannabinoid (CBD) clinical stage pain relief products. The Company believes that if all goes well, its flagship drug, PPP001, designed to treat the chronic pain associated with many cancers, will be on the market in 2019. The Canadian Cancer Society is estimating a 35{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} growth rate in cancer cases in Quebec, and 40{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} nationally by 2030. They also advocate for more spending on research on innovative drugs and end-of-life treatment.
Tetra Bio-Pharma is accelerating the acceptance of cannabis-based medical treatments. It is the only bio-pharmaceutical company currently running a double-blind Phase 1 study. It aims to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of single and multi-daily ascending doses of cannabis by smoking in healthy volunteers.
Pending a positive outcome, cannabis-based drugs designed to treat cancer pain and nausea from chemotherapy, PTSD and a number of other ailments will qualify for North-American Drug Identification Numbers (DIN). This means that prescriptions would be eligible for insurance coverage.
In addition to developing proprietary products and intellectual property, Tetra Bio-Pharma signed a supply agreement with ACMPR licensed producer Aphria Inc. on November 3, 2016. The Tetra-Aphria partnership was further solidified on April 19, 2017 when plans were announced for the joint distribution of dried medical cannabis for Quebec and the Atlantic Provinces.
The Momentum PR informative and comprehensive report on Tetra Bio-Pharma is available on the Momentum PR LinkedIn page.
If you would like more information on Tetra Bio-Pharma listed on the Canadian Securities Exchange under the symbol TBP with a market cap of C$ 70 million, or would like to arrange an interview with management please contact:
Momentum PR
Juliette Benard, Director Media Relations
+1.450.332.6939
About Momentum PR
Momentum PR is a cutting-edge public and investor relations consulting agency representing companies within the Canadian investment community.
Since 2009, Momentum PR has been servicing small and mid cap Canadian listed public companies, seeking to increase their exposure across North America. The focus at Momentum PR is on building and driving brand awareness. Momentum PR cultivates new audiences in the media and investment communities by proactively engaging interested parties on behalf of client companies through online and offline channels.
Disclaimer:
All editorial content contained herein is solely the responsibility of Momentum PR and does not reflect, in any way, the opinions of TheNewswire.ca Inc., its partner newswires and / or associated news services.
– See more at: The Newswire
- Published in Blog, Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
Tetra Bio-Pharma Plays to Its Strengths with Pharma Approach, Plus Exclusive Interview — CFN Media
Tetra Bio-Pharma Plays to Its Strengths with Pharma Approach, Plus Exclusive Interview — CFN Media
SEATTLE, WA–(Marketwired – May 4, 2017) – CFN Media Group (“CannabisFN”), the leading creative agency and digital media network dedicated to legal cannabis, announces publication of an exclusive interview and article discussing Tetra Bio-Pharma Inc. (CSE: TBP) (OTCQB: GRPOF) and its transition to a pharmaceutical-like approach to the cannabis industry. The interview is with Dr. Guy Chamberland, Tetra’s Chief Science Officer.
Smoked Cannabis Trials
Most mainstream physicians are hesitant to recommend the use of medical marijuana to treat any medical conditions due to the lack of controlled clinical trials. In many cases, there’s only anecdotal evidence of efficacy in treating certain medical conditions and several studies have shown possible negative side effects. There’s also a huge difference between various strains available on their market and very little data supporting one over another.
Tetra Bio-Pharma’s flagship clinical program intends to assess the safety and efficacy of smoked marijuana in treating pain in patients with cancer and AIDS. By doing so, the company aims to achieve prescription drug coverage to make medical marijuana more affordable for patients while reassuring physicians that the treatment is both safe and efficacious. The move could have tremendous implications for the industry that still struggles with a negative stereotype.
The team worked closely with U.S. and Canadian regulators to design and implement a Phase I safety trial (ongoing) that will eventually move to a large-scale Phase III efficacy trial targeting pain in patients where opioids and other options have been ineffective.
Partnerships
Tetra Bio-Pharma has recently unveiled several different partnerships that help expand its footprint and advance its clinical pipeline. On April 3, the company announced a definitive agreement to develop and commercialize a drug product containing dronabinol for the management of anorexia and cancer chemotherapy-related pain. The new product will be an oral mucoadhesive tablet based on IntelGenx’s proprietary AdVersa® technology, which avoids common side effects associated with the original drug, including upset stomach and headache.
On April 19, the company announced plans for the joint distribution of dried medical cannabis in the Maritime Provinces and Quebec with Aphria Inc. The agreement provides the company with dried cannabis for use in its aforementioned clinical trial program while generating near-term revenue to help finance the program’s development. This helps the company avoid the cost of establishing its own grow operations.
Please follow the link to read the full article and see the interview: http://www.cannabisfn.com/tetra-bio-pharma-plays-strengths-pharma-approach-plus-exclusive-interview/
Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/become-featured-company/
Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8
Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone:http://www.cannabisfn.com
About CFN Media
CFN Media (CannabisFN), the leading creative agency and media network dedicated to legal cannabis, helps marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.
CFN launched in June of 2013 to initially serve the growing universe of publicly traded marijuana companies across North America. Today, CFN Media is also the digital media choice for the emerging brands in the space.
Disclaimer:
Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns CFN Media and CannabisFN.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/.
- Published in Medical Marijuana, News Home, Tetra Bio Pharma
Momentum Reports – Tetra Bio-Pharma CSE:TBP – April 2017
Momentum Reports – Tetra Bio-Pharma CSE:TBP – April 2017
- Published in Blog, Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
Tetra Bio-Pharma and IntelGenx Announce the Signing of a Definitive Agreement for the Development and Commercialization of a Dronabinol XL Tablet
IntelGenx and Tetra Bio-Pharma Announce the Signing of a Definitive Agreement for the Development and Commercialization of a Dronabinol XL Tablet
Tetra Bio-Pharma Inc. (“Tetra“) (CSE:TBP)(OTC PINK:GRPOF) and IntelGenx Corp. (“IntelGenx”) (TSX VENTURE:IGX)(OTCQX:IGXT), today announced the signing of a definitive agreement for the development and commercialization of a drug product containing the cannabinoid Dronabinol (the “Product”) for the management of anorexia and cancer chemotherapy-related pain. This definitive agreement follows the binding term sheet between the two companies that was announced on February 9, 2017.
Pursuant to the definitive agreement, Tetra has exclusive rights to sell the Product in North America, with a right of first negotiation for territories outside of the United States and Canada. Tetra will make an upfront payment to IntelGenx, in addition to set future milestone and royalty payments, based on the completion of an efficacy study, approvals from the U.S. Food and Drug Association (“FDA”) and Health Canada, and the commercial launch of the Product. IntelGenx will be responsible for the research and development of the Product, including clinical studies, and will develop the product as an oral mucoadhesive tablet based on its proprietary AdVersa® controlled-release technology. Tetra will be responsible for funding the product development, and will own and control all regulatory approvals, including the related applications, and any other marketing authorizations. Tetra will also be responsible for all aspects of commercializing the Product.
“The U.S. cancer pain market is expected to reach $5 billion in 2018, and the quick growing medical cannabis industry is poised to capture a signature portion of that opportunity,” said Dr. Horst G. Zerbe, President and CEO of IntelGenx. “We are pleased to be working with Tetra to bring this much-needed cannabinoid product to North American patients suffering from anorexia and cancer chemotherapy-related pain.”
“We are pleased to announce the signing of the definitive agreement with IntelGenx and look forward to working very hard with them to bring this much-needed product to patients suffering from cancer pain,” said Andre Rancourt, CEO of Tetra. “The execution of this agreement is just the beginning for Tetra as we look forward to aggressively concluding future agreements as we build a leading bio-pharmaceutical organization focused on developing medicinal cannabis as pharmaceutical drugs.”
Background Information
There are many clinical problems associated with the use of currently available form of Dronabinol in patients with anorexia and cancer chemotherapy-related pain. It has been demonstrated that psychoactive drugs exert their euphoria, and other psychoactive effects, when the blood levels of the drug rapidly increase. The pharmacokinetic profile of tetrahydrocannabinol (“THC”) and its metabolite increases the abuse potential of cannabinoids like Dronabinol. The significant advantage of an oral mucoadhesive tablet based on IntelGenx’ proprietary AdVersa®controlled-release technology is that it can be adjusted to achieve a predetermined drug release pattern by increasing the residence time, promoting intimate contact with the mucosal tissue and increasing the bioadhesive properties of the dosage form. It is believed that, by deploying this technology in the controlled-release of THC, a longer time release of the drug will be achieved and, thereby, a rapid increase in the blood will be avoided. There will also potentially be improved bioavailability and reduced gastro-intestinal side effects, making a sustained-release THC product a promising alternative in the battle for the reduction of opioids in patients with chronic pain.
About Tetra Bio Pharma
Tetra Bio Pharma is a multi-subsidiary publicly traded company (CSE:TBP) (OTC PINK:GRPOF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.
Tetra Bio Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.
About IntelGenx
IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform. Established in 2003, the Montreal-based company is listed on the TSX-V and OTC-QX.
IntelGenx highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx state-of-the art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to our clients. More information is available about the company at: www.intelgenx.com.
- Published in Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
Tetra (TBP:CSE), IntelGenx to develop cancer-pain-relief drug
Tetra Bio-Pharma and IntelGenx Announce the Signing of a Term Sheet for the Development and Commercialization of a Dronabinol XL Tablet
– Momentum Public Relations –
Press Release: February 9th, 2017
Tetra Bio-Pharma Inc. (“Tetra“) (CSE:TBP)(CSE:TBP.CN)(OTC PINK:GRPOF) and IntelGenx Corp. (“IntelGenx”), (TSX VENTURE:IGX)(OTCQX:IGXT), today announced the signing of a binding term sheet for the development and commercialization of a drug product containing dronabinol. Under the binding term sheet, Tetra will have exclusive rights to sell the product in North America with a right of first negotiation for outside the U.S. and Canada. The U.S. cancer pain market is expected to reach $5 billion in 2018.
Per the Binding Term Sheet, Tetra will make a non-refundable exclusive negotiation payment to IntelGenx, an upfront payment along with set milestone payments based on the completion of an efficacy study, approvals from FDA and Health Canada and launching of the product.
IntelGenx will be responsible for the research and development of the product, including clinical studies and will develop the product as an oral mucoadhesive tablet based on its proprietary AdVersa® controlled-release technology. Tetra will be responsible for funding the product development, and will own and control all regulatory approvals, including the application and any other marketing authorizations. Tetra will also be responsible for all aspects of commercializing the drug product.
“We are pleased to partner with Tetra Bio-Pharma to enter the lucrative cannabis market,” said Dr. Horst G. Zerbe, President and CEO of IntelGenx. “We will work with Tetra to bring this much needed THC product to North American patients suffering from anorexia and cancer chemotherapy-related pain. This announcement is a further testament to the strength of IntelGenx’ scientists who continue to execute the development of innovative products using our advanced oral delivery platforms.”
PhytoPain Pharma Inc., a subsidiary of Tetra will be submitting a request for a Type B pre-IND meeting with the Division of Anesthesia, Analgesia, and Addiction Products (DAAAP), Center for Drug Evaluation and Research (CDER), USA Food and Drug Administration (FDA) to discuss the marketing requirements for Dronabinol AdVersa® Mucoadhesive tablet product. Tetra intends on developing Dronabinol AdVersa® Mucoadhesive tablet as an analgesic for the management of Breakthrough Cancer Pain. Once the safety and efficacy is demonstrated in patients, this drug product will be eligible for approval under the 505(b)(2) New Drug Application (NDA) path commented Dr. Guy Chamberland, Chief Scientific Officer and Regulatory Affairs. The 505(b)(2) pathway represents a significant reduction in time and cost to market commented Dr. Chamberland. He added that the company will also be meeting with the Therapeutic Product Directorate, Health Canada to discuss the clinical development and marketing requirements.
Dr. Chamberland further commented that there are many clinical problems associated with the use of currently available form of Dronabinol in patients with anorexia and cancer chemotherapy. It has been demonstrated that psychoactive drugs exert their euphoria, and other psychoactive effects, when the blood levels of the drug rapidly increase. The pharmacokinetic profile of THC and its metabolite significantly affect the abuse potential of Dronabinol. The significant advantage of the Mucoadhesive technology is the controlled-release of THC resulting in a longer time release of the drug avoiding a rapid increase in the blood. There is also an improved bioavailability and potentially reduced gastro-intestinal side effects making the sustained-release THC product a promising alternative in the battle for the reduction of opioids in patients with chronic pain.
About IntelGenx:
IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilmTM technology platform. Established in 2003, the Montreal-based company is listed on the TSX-V and OTC-QX.
IntelGenx highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx state-of-the art manufacturing facility, established for the VersaFilmTM technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to our clients. More information is available about the company at: www.intelgenx.com.
About Tetra Bio Pharma:
Tetra Bio-Pharma is a multi subsidiary publicly traded company (CSE:TBP)(CSE:TBP.CN)(OTC PINK:GRPOF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.
Tetra Bio Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.
The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.
- Published in Medical Marijuana, News Home, Tetra Bio Pharma